Specifically, Achilles will test the Ori manufacturing platform on its proprietary clonal neoantigen T-cell (cNeT) therapy manufacturing process.

Ori's proprietary platform is designed to close, automate, and standardize manufacturing to help therapeutics developers further develop and advance their products from preclinical process development to commercial-scale manufacturing. Achilles Therapeutics develops cancer immunotherapies targeting clonal neoantigens -- protein markers unique to each individual that are expressed on the surface of every cancer cell -- using DNA sequencing data from each patient.

"We believe that collaborating with therapy developers early is key to maximizing the scalability and repeatability of these often-complicated manufacturing processes," said Jason C. Foster, CEO of Ori Biotech, in a statement.